Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment

被引：4

作者：

Prezioso, Carla ^{[1
,2
]}

Ciotti, Marco ^{[3
]}

Brazzini, Gabriele ^{[2
]}

Piacentini, Francesca ^{[2
]}

Passerini, Sara ^{[2
]}

Grimaldi, Alfonso ^{[4
]}

Landi, Doriana ^{[4
,5
]}

Nicoletti, Carolina Gabri ^{[4
,5
]}

Zingaropoli, Maria Antonella ^{[2
]}

Iannetta, Marco ^{[5
]}

Altieri, Marta ^{[6
]}

Conte, Antonella ^{[6
,7
]}

Limongi, Dolores ^{[8
]}

Marfia, Girolama Alessandra ^{[5
,9
]}

Ciardi, Maria Rosa ^{[2
]}

Mastroianni, Claudio Maria ^{[2
]}

Palamara, Anna Teresa ^{[10
,11
]}

Moens, Ugo ^{[12
]}

Pietropaolo, Valeria ^{[2
]}

机构：

[1] IRCSS San Raffaele Roma, Microbiol Chron Neurodegenerat Pathol, I-00163 Rome, Italy

[2] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy

[3] Polyclin Tor Vergata Fdn, Virol Lab, I-00133 Rome, Italy

[4] Fdn Policlin Tor Vergata, Multiple Sclerosis Clin & Res Unit, I-00133 Rome, Italy

[5] Tor Vergata Univ, Dept Syst Med, I-00133 Rome, Italy

[6] Sapienza Univ Rome, Dept Human Neurosci, I-00185 Rome, Italy

[7] IRCCS Neuromed, I-86077 Pozzilli, IS, Italy

[8] Telemat Univ, IRCCS San Raffaele Roma, I-00163 Rome, Italy

[9] IRCCS Ist Neurol Mediterraneo NEUROMED, Neurol Unit, I-86077 Pozzilli, IS, Italy

[10] Ist Super Sanita, Dept Infect Dis, I-00161 Rome, Italy

[11] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Cenci Bolognetti Fdn, Lab Inst Pasteur Italia, I-00185 Rome, Italy

[12] Arctic Univ Norway, Univ Tromso, Fac Hlth Sci, Dept Med Biol, N-9037 Tromso, Norway

来源：

JOURNAL OF CLINICAL MEDICINE | 2022年 / 11卷 / 02期

关键词：

progressive multifocal leukoencephalopathy; natalizumab; ocrelizumab; dimethyl-fumarate; fingolimod; JCPyV infection; non-coding control region; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CEREBROSPINAL-FLUID; PML RISK; NATALIZUMAB; INFECTION; DISEASE; PLASMA; BLOOD; PATHOGENESIS; REPLICATION;

D O I：

10.3390/jcm11020347

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Markers of JC polyomavirus (JCPyV) activity can be used to evaluate the risk of progressive multifocal leukoencephalopathy (PML) in treated multiple sclerosis (MS) patients. The presence of JCPyV DNA and microRNA (miR-J1-5p), the anti-JCV index and the sequence of the non-coding control region (NCCR) in urine and plasma were determined in 42 MS subjects before treatment (T0), 6 months (T6) and 12 months (T12) after natalizumab, ocrelizumab, fingolimod or dimethyl-fumarate administration and in 25 healthy controls (HC). The number of MS patients with viruria increased from 43% at T0 to 100% at T12, whereas it remained similar for the HC group (35-40%). Viremia first occurred 6 months after treatment in MS patients and increased after 12 months, whereas it was absent in HC. The viral load in urine and plasma from the MS cohort increased over time, mostly pronounced in natalizumab-treated patients, whereas it persisted in HC. The archetypal NCCR was detected in all positive urine, whereas mutations were observed in plasma-derived NCCRs resulting in a more neurotropic variant. The prevalence and miR-J1-5p copy number in MS urine and plasma dropped after treatment, whereas they remained similar in HC specimens. Viruria and miR-J1-5p expression did not correlate with anti-JCV index. In conclusion, analyzing JCPyV DNA and miR-J1-5p levels may allow monitoring JCPyV activity and predicting MS patients at risk of developing PML.

引用

页数：16

共 12 条

[11] CD49D EXPRESSION ON T LYMPHOCYTES AND CD8 EFFECTOR PERCENTAGE AS PREDICTORS OF JC VIRUS REACTIVATION IN MULTIPLE SCLEROSIS PATIENTS ON NATALIZUMAB TREATMENT
Iannetta, M.
Zingaropoli, M. A.
Bellizzi, A.
Anzivino, E.
D'Abramo, A.
Oliva, A.
Morreale, M.
Pontecorvo, S.
Lo Menzo, S.
Pietropaolo, V.
Francia, A.
Mastroianni, C. M.
Vullo, V.
Ciardi, M. R.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2016, 36 : 254 - 254
[12] Increased endogenous catecholamine production, beta2-adrenoceptor and dopamine D5 receptor expression in circulating lymphocytes from patients with multiple sclerosis undergoing interferon-beta treatment
Zaffaroni, M.
Cosentino, M.
Marino, F.
Ferrari, M.
Carcano, E.
Perusin, M.
Rasini, E.
Bombelli, R.
Rizzo, A.
Ghezzi, A.
Comi, G.
Lecchini, S.
Antonio, S.
MULTIPLE SCLEROSIS, 2006, 12 : S193 - S193

← 1 2 →